Waldenström macroglobulinemia: biology, genetics, and therapy
Jonas Paludo,1,2 Stephen M Ansell,1 1Division of Hematology, 2Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA Abstract: Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity characterized by the presence of a lymphoplasmacytic lymphoma, a non-Hodgkin lympho...
Enregistré dans:
Auteurs principaux: | Paludo J, Ansell SM |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/91e020a8d5054da7b86d0f67cce9353a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
par: C. I. Edvard Smith, et autres
Publié: (2021) -
Macroglobulinemia de Waldenström. Experiencia de 15 años en el Hospital del Salvador, Santiago, Chile
par: Cardemil,Daniela, et autres
Publié: (2019) -
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
par: Ujjani C, et autres
Publié: (2020) -
Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission
par: Seegobin K, et autres
Publié: (2021) -
Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
par: Carrà G, et autres
Publié: (2019)